Unregistered Sales of Equity Securities · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Other Events
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On November 5, 2026, the majority of the holders of its Series X Preferred shares, with over 54% of votes available, approved the amendment of its Certificate of Designation to increase the authorized shares from five hundred million (500,000,000) to one billion (1,000,000,000).…
Filed Nov 6, 2026Accepted Nov 6, 2026, 4:01 PM ESTCIK 802257Accession 0001185185-26-005236
Mitesco, Inc. (the “Company,” “we,” “us,” or “our”) was formed in the state of Delaware on January 18, 2012. On December 9, 2015, we restructured our operations and acquired Newco4pharmacy, LLC, a development stage company which sought to acquire compounding pharmacy businesses. As a part of the restructuring, we shut down our former business line. On April 24, 2020, we changed our name to Mitesco, Inc. In October 2023, the Company changed its domicile from Delaware to Nevada in order to effect reduced costs.
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 5.03Item 5.03 - Amendments to Articles/Bylaws
Item
5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On
November 5, 2026, the majority of the holders of its Series X Preferred shares, with over 54% of votes available, approved the amendment
of its Certificate of Designation to increase the authorized shares from five hundred million (500,000,000) to one billion (1,000,000,000).
The Board of Directors has approved this action and is taking all steps necessary to implement the change. The Company will file an information
statement as soon as practical informing the shareholders of the change. The Company currently has approximately 60 million shares outstanding
and around 20 million shares in the float.
Item 3.02Item 3.02 - Unregistered Sales of Equity
Item
3.02 Unregistered Sales of Equity Securities.
Series
X Preferred Stock issuance for compensation
On
November 5, 2026 the Board of Directors approved the issuance of additional shares of its Series X Preferred stock to its three (3) directors
and one (1) existing holder as consideration for work on its acquisition matters. Mack Leath was issued an additional 4,800 shares bringing
his total Series X Preferred holdings to 12,000 shares. Brian Valania was issued an additional 4,800 shares bringing his total Series
X Preferred holdings to 12,000 shares. Frank Panunto was issued an additional 4,800 shares bringing his total Series X Preferred holdings
to 12,000 shares. Anglo Irish Management, LLC was issued an additional 4,800 shares bringing their total holdings of Series X Preferred
shares to 43,103 shares.
As
a result of this issuance the Company now has 91,103 shares of its 10% Series X Cumulative Redeemable Perpetual Preferred Stock
(the “Series X Preferred Stock”) outstanding. The Series X Preferred Stock has a par value of $0.01 per share, no stated
maturity, a liquidation preference of $25.00 per share, and will not be subject to any sinking fund or mandatory redemption and
will remain outstanding indefinitely unless the Company decides to redeem or otherwise repurchase the Series X Preferred Stock; the Series
X Preferred Stock is not redeemable prior to November 4, 2020. The Series X Preferred Stock will rank senior to all classes of the Company’s
common and preferred stock and accrues dividends at the rate of 10% per annum on $25.00 per share. Beginning in October 2024, the
Company elected to use the closing stock price on the 15 th of each month to determine the number of shares to be issued
in payment of the dividend. Each one share of the Series X Preferred Stock is entitled to 400 votes on all matters submitted to
a vote of our shareholders, and as of the date of this filing the holders of its Series X Preferred shares have over 5% voting control
of the Company’s stock.
As a result of these issuances the Board of Directors has sufficient
shares votes in aggregate for approximately 25% of the share votes available, while Anglo Irish Management, LLC has approximately 24%
of the share votes available. Five (5) of the holders, including a former Board member, have voting control for any matters requiring
approval with over 54% of the votes available. When the other Series X Preferred holders are included the group made up of all Series
X Preferred holders has in total voting rights for over 57% of the shares available to vote.
The
securities described have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States absent
registration or an applicable exemption from the registration requirements.
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
On
November 5, 2026 the Board of Directors approved the issuance of additional shares of its Series X Preferred stock to its three (3) directors.
Mack Leath was issued an additional 4,800 shares bringing his total Series X Preferred holdings to 12,000 shares. Brian Valania was issued
an additional 4,800 shares bringing his total Series X Preferred holdings to 12,000 shares. Frank Panunto was issued an additional 4,800
shares bringing his total Series X Preferred holdings to 12,000 shares.
Item 8.01Item 8.01 - Other Events
Item
8.01 Other Events.
The
Company continues discussions with a number of acquisition candidates and the restructuring of its Bridge notes and Series A Preferred
shares. The change in the number of authorized shares of its common stock was not related to any particular transaction or event.